Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know

Jonathan Ponciano, The Motley Fool

Sun, August 23, 2026 at 2:14 PM GMT+3 4 min read

CAH +1.25%

Jessica L. Mayer, chief legal officer of Cardinal Health, Inc. (NYSE:CAH), sold 29,436 shares of common stock at $236.19 per share on August 18, according to an SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($236.19); post-transaction value based on the August 18 market close ($234.98).

Key questions

What were the execution details of the transaction?
The shares were sold in multiple transactions at price intervals ranging from $234.07 to $237.67 per share.
How does this move impact the insider's total ownership?
Following the disposition, Mayer direct ownership interest in the company is 0.01%.
What is the current scale and valuation of the company?
Cardinal Health operates as a global healthcare services provider with a $55.0 billion market capitalization and trailing twelve-month revenue of $254.2 billion as of the August 19 market close.

Company Overview

Company Snapshot

Cardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical supplies, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.
The company generates revenue through its two core operating divisions--Pharmaceutical and Medical--which provide distribution, logistics, and specialized healthcare services to institutional and individual customers.
Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home-based care.

Cardinal Health is one of the largest healthcare services and products companies globally. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health's scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.

What this transaction means for investors

Mayer wasn't alone on Aug. 18. CFO Aaron Alt sold 42,000 shares the same day, and CIO Michelle Greene sold 11,650, for example, and all three had performance share units settle on Aug. 15. Though the filing seems routine, Mayer's seat is what makes the filing worth reading. Analysts spent much of the Aug. 11 earnings call pressing management on 340B, the federal program requiring discounted drug prices for hospitals that serve low-income patients, plus Medicare price setting under the Inflation Reduction Act. CEO Jason Hollar was blunt about it, saying "we don't see our role changing and we don't believe our compensation should change."

Fiscal 2027 pharma revenue growth of 3% to 5% already builds in IRA pricing pressure, and Alt said the company is assuming the same percentage impact it just absorbed, roughly 500 basis points off segment revenue in the fourth quarter, offset almost exactly by GLP-1 volume. The January rate changes are the first live test of whether that offset holds.

Should you buy stock in Cardinal Health right now?

Before you buy stock in Cardinal Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cardinal Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $429,223!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,318,055!*

Now, it's worth noting Stock Advisor's total average return is 965% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of August 23, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know was originally published by The Motley Fool